Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Shares Outstanding: 2020-2025

Historic Shares Outstanding for Janux Therapeutics (JANX) over the last 6 years, with Sep 2025 value amounting to $60.1 million.

  • Janux Therapeutics' Shares Outstanding rose 14.88% to $60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.1 million, marking a year-over-year increase of 14.88%. This contributed to the annual value of $59.1 million for FY2024, which is 27.70% up from last year.
  • Latest data reveals that Janux Therapeutics reported Shares Outstanding of $60.1 million as of Q3 2025, which was up 1.39% from $59.3 million recorded in Q2 2025.
  • Janux Therapeutics' Shares Outstanding's 5-year high stood at $60.1 million during Q3 2025, with a 5-year trough of $1.2 million in Q1 2021.
  • Its 3-year average for Shares Outstanding is $51.8 million, with a median of $52.2 million in 2024.
  • Data for Janux Therapeutics' Shares Outstanding shows a peak YoY surged of 4,383.61% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Janux Therapeutics' Shares Outstanding stood at $41.2 million in 2021, then rose by 0.90% to $41.6 million in 2022, then grew by 11.14% to $46.3 million in 2023, then increased by 27.70% to $59.1 million in 2024, then climbed by 14.88% to $60.1 million in 2025.
  • Its Shares Outstanding stands at $60.1 million for Q3 2025, versus $59.3 million for Q2 2025 and $59.2 million for Q1 2025.